Integrated Training in Pharmacological Sciences

描述(由申请者提供)：西奈山药理学综合培训项目旨在提供严格的多学科博士前研究教育，培养项目毕业生提高新药发现的能力。不同的方法将包括确定新的靶点、新的筛查或结构信息以告知药物设计、预测/展示药物的安全性及其副作用的方法，以及预测已被批准使用的药物的再利用机会的方法。拥有这种技能的科学家的需求是显而易见的，因为我们面临以下问题：正在开发的新疗法匮乏；针对太多疾病缺乏有效的治疗选择；不同个体对特定药物的反应范围之广令人困惑；需要创新的治疗选择，包括药物组合和克服耐药性的新策略。培训计划将使受训人员在计算和系统生物学方面应用于“组学”和其他大型数据集分析，为疾病的新可测试模型提供信息，并揭示潜在的新治疗策略。这些方法将成为一些受训者的项目领域，而另一些人则采用结构或化学方法来开发有关新靶点的信息或为新药的设计提供信息。一些学员将专注于开发可应用于疾病或治疗相关网络分析的新计算工具，而另一些学员则专注于特定的生物医学问题。该培训计划培养具有这些不同专业的学员利用彼此的专业知识进行协作的能力。拟议的每年最多12名受训人员通常将从培训计划中获得2-3年的支持，分别从博士和医学博士/博士学生的第一个或头两个培训年后开始。博士学位通常在入学后5.5年内完成。这个由42名教员组成的高度合作的小组来自11个不同的系，既有基础科学系，也有临床系。它包括来自药理学和系统治疗学系的17名教职员工和来自结构和化学生物学系的5名教职员工，这两个系是全校实验治疗研究所(ETI)的主要贡献系。ETI为研究小组提供了使用新兴药物开发工具的途径。大多数学员在研究生院疾病系统生物学和治疗学培训领域攻读博士课程，大多数参与培训的教职员工都为教学工作做出了贡献。该计划的毕业生在一系列令人满意的学术和制药环境和其他途径中使用他们的培训，在其中他们应用他们从博士前培训中带来的特殊技能。

DESCRIPTION (provided by applicant): The Integrated Training in Pharmacological Sciences Program at Mount Sinai aims to provide rigorous multi- disciplinary pre-doctoral research education that fosters the ability of Program graduates to enhance discovery of new drugs. The diverse approaches will include identification of new targets, new screens or structural information to inform drug design, methods for prediction/demonstration of the safety of a drug and its side effects, and methods to predict opportunities for re-purposing drugs that have already been in approved use. The need for scientists with such skills is clear since we face: a paucity of new therapeutics in the pipeline; a lack of effective therapeutic options for too many diseases; a perplexingly wide range of responses among different individuals to a particular drug; and a need for innovative therapeutic options that include drug combinations and new strategies to overcome drug resistance. The Training Program will engage trainees in computational and systems biological applications to the "omics" and other large data set analyses that inform new testable models of disease and reveal potential new therapeutic strategies. These approaches will become the project areas for some trainees, while others pursue structural or chemical approaches to develop information about new targets or to inform the design of new drugs. Some trainees will focus on developing the new computational tools that can be applied to disease- or therapeutic-related network analyses, while others focus on particular biomedical problems. The Training Program fosters the ability of trainees with these diverse specializations to take collaborative advantage of each other's expertise. The proposed group of up to 12 trainees per year will typically receive support from the Training Program for 2-3 years, starting after the first or first two training years for Ph.D. and MD/Ph.D. students, respectively. The Ph.D. degree is typically completed within 5.5 years from matriculation. The highly collaborative group of 42 participating faculty members comes from 11 different departments, both basic science and clinical. It includes 17 faculty members from the Pharmacology and Systems Therapeutics Department and 5 from the Structural and Chemical Biology Department, the major contributing departments to the school-wide Experimental Therapeutics Institute (ETI). ETI provides research groups with access to emerging tools for drug development. Most trainees pursue their Ph.D. coursework in the Systems Biology of Disease and Therapeutics training area of the Graduate School and most participating faculty contribute to the teaching efforts. Graduates of the Program, use their training in a gratifying array of academic and pharmaceutical settings and other paths, in which they apply the special skill sets they bring from their pre-doctoral training.